Antonio Duran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio Duran has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
A. Bhimaraj
Houston Methodist Hosp, Houston, TX USA
5 shared publicationsA. Guha
Houston Methodist Hosp, Houston, TX USA
5 shared publicationsB. Trachtenberg
Houston Methodist Hosp, Houston, TX USA
5 shared publicationsF. Hussain
Houston Methodist Hosp, Houston, TX USA
5 shared publicationsI. Hussain
Houston Methodist Hosp, Houston, TX USA
5 shared publicationsJ. Estep
Houston Methodist Hosp, Houston, TX USA
5 shared publications
Latest Publications
- 3 May 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (8) , 101239
Preimplant Hyponatremia Does Not Predict Adverse Outcomes in Patients With Left Ventricular Assist Devices
- 3 May 2022
- Published by Elsevier in Current Problems in Cardiology
- Vol. 48 (8) , 101239
Preimplant Hyponatremia Does Not Predict Adverse Outcomes in Patients With Left Ventricular Assist Devices
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S67-S68
Hyponatremia Does Not Predict Adverse Outcomes In Patient With Left Ventricular Assist Devices
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S67-S68
Hyponatremia Does Not Predict Adverse Outcomes In Patient With Left Ventricular Assist Devices
- 27 February 2022
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 72, 84-92
Prosthesis-patient mismatch following aortic and mitral valves replacement – A comprehensive review
- 27 February 2022
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 72, 84-92
Prosthesis-patient mismatch following aortic and mitral valves replacement – A comprehensive review
- 9 February 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 352, 98-99
The era of heart failure risk prediction models, is it time to test their utility?
- 9 February 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 352, 98-99
The era of heart failure risk prediction models, is it time to test their utility?
- 19 June 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 338, 145-146
FGF23 predicts outcomes in heart failure but questions remain unanswered
- 19 June 2021
- Published by Elsevier in International Journal of Cardiology
- Vol. 338, 145-146
FGF23 predicts outcomes in heart failure but questions remain unanswered
- 1 March 2021
- Published by Elsevier in Current Problems in Cardiology
- Vol. 46 (3) , 100624
Transaxillary TAVR Leads to Shorter Ventilator Duration and Hospital Length of Stay Compared to Transapical TAVR
- 1 March 2021
- Published by Elsevier in Current Problems in Cardiology
- Vol. 46 (3) , 100624
Transaxillary TAVR Leads to Shorter Ventilator Duration and Hospital Length of Stay Compared to Transapical TAVR
- Open Access
- 1 December 2020
- Published by Elsevier in JACC: Case Reports
- Vol. 2 (15) , 2358-2362
Use of TandemHeart as Bridge to Recovery for Antibody-Mediated Rejection in a Heart Transplant Patient
- 1 December 2020
- Published by Elsevier in JACC: Case Reports
- Vol. 2 (15) , 2358-2362
Open AccessUse of TandemHeart as Bridge to Recovery for Antibody-Mediated Rejection in a Heart Transplant Patient
- 10 August 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (6) , 1296-1303
Outcomes following endovascular therapy for acute stroke by interventional cardiologists
Objectives To summarize the outcomes of acute ischemic stroke (AIS) intervention by interventional cardiologists (IC) working on a stroke team. Background There is a geographic maldistribution of dedicated neuro‐interventionalists (NI) to treat large vessel occlusion (LVO) AIS. Methods Results of 166 consecutive patients who received endovascular therapy (EVT) for AIS due to LVO by IC at three centers between 2009 and 2019 are reported. A modified Rankin score (mRs) of ≤ 2 at 90 days after EVT was used as the primary measurement of a good neurological outcome. Univariate logistic regression was used to evaluate predictors of the mRS > 2 and mortality. Those variables with significance of p < .2 from the univariate analysis were included in a multivariate analysis. Results All‐cause mortality at 30 days was 22%. A favorable clinical outcome, mRS ≤ 2 at 90 days, was 49%. After multivariate analysis and controlling for confounders, a higher baseline NIHSS was predictive of 30‐day mortality (OR 1.20 [95% CI 1.09–1.32] p < .001) and unfavorable clinical outcome (mRS > 2) at 90 days (OR 1.16 [95% CI 1.07–1.25] p < .001). Conclusion Outcomes for carotid stent capable IC performing EVT for AIS are comparable to those achieved by NI physicians in major randomized clinical trials. Our data supports conducting a clinical trial of carotid stent capable IC working on multidisciplinary stroke teams to perform EVT for AIS due to LVO in communities and hospitals without timely access (<60 min by ground transport) to dedicated NI.
- 10 August 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (6) , 1296-1303
Outcomes following endovascular therapy for acute stroke by interventional cardiologists
Objectives To summarize the outcomes of acute ischemic stroke (AIS) intervention by interventional cardiologists (IC) working on a stroke team. Background There is a geographic maldistribution of dedicated neuro‐interventionalists (NI) to treat large vessel occlusion (LVO) AIS. Methods Results of 166 consecutive patients who received endovascular therapy (EVT) for AIS due to LVO by IC at three centers between 2009 and 2019 are reported. A modified Rankin score (mRs) of ≤ 2 at 90 days after EVT was used as the primary measurement of a good neurological outcome. Univariate logistic regression was used to evaluate predictors of the mRS > 2 and mortality. Those variables with significance of p < .2 from the univariate analysis were included in a multivariate analysis. Results All‐cause mortality at 30 days was 22%. A favorable clinical outcome, mRS ≤ 2 at 90 days, was 49%. After multivariate analysis and controlling for confounders, a higher baseline NIHSS was predictive of 30‐day mortality (OR 1.20 [95% CI 1.09–1.32] p < .001) and unfavorable clinical outcome (mRS > 2) at 90 days (OR 1.16 [95% CI 1.07–1.25] p < .001). Conclusion Outcomes for carotid stent capable IC performing EVT for AIS are comparable to those achieved by NI physicians in major randomized clinical trials. Our data supports conducting a clinical trial of carotid stent capable IC working on multidisciplinary stroke teams to perform EVT for AIS due to LVO in communities and hospitals without timely access (<60 min by ground transport) to dedicated NI.
- 23 April 2020
- Published by Wiley in Journal of Digestive Diseases
- Vol. 21 (5) , 264-271
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Objective: There are limited data on using more than one biologic or small molecule drug combined to treat patients with inflammatory bowel disease. The aim of our study was to determine the effectiveness and safety of combination biologic use in inflammatory bowel disease.Methods: We identified patients with Crohn's disease or ulcerative colitis who received treatment with a combination of two biologics or a biologic and a small molecule drug from 2015 to 2019 for persistent disease activity or concomitant rheumatological or dermatological disease. The primary end‐point was effectiveness, based on improvements in inflammatory markers, clinical, and endoscopic remission. The secondary end‐point was safety.Results: Of the 50 patients treated with combination therapy there were significantly more patients in clinical and endoscopic remission at follow‐up compared to baseline (50% vs 14%, P = 0.0018, delta 36%, 95% confidence interval [CI] 0.13‐0.53; and 34% vs 6%, P = 0.0039, delta 28%, 95% CI 0.09‐0.47), respectively. Median erythrocyte sedimentation rate (17 mm/h vs 13 mm/h, P = 0.002) and C‐reactive protein (5.00 mg/dL vs 2.35 mg/dL, P = 0.002) also decreased posttreatment. There were eight serious adverse events and no deathsConclusions: Combination biologic therapy appears to be an effective option for patients with refractory inflammatory bowel disease or concomitant autoimmune disease that is inadequately controlled by biologic monotherapy. There was an increased risk of serious infection compared with biologic monotherapy; however, this risk might be minimized by discontinuing immunomodulators prior to initiating combination therapy. Large prospective studies are needed to confirm these findings.
- 23 April 2020
- Published by Wiley in Journal of Digestive Diseases
- Vol. 21 (5) , 264-271
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Objective: There are limited data on using more than one biologic or small molecule drug combined to treat patients with inflammatory bowel disease. The aim of our study was to determine the effectiveness and safety of combination biologic use in inflammatory bowel disease.Methods: We identified patients with Crohn's disease or ulcerative colitis who received treatment with a combination of two biologics or a biologic and a small molecule drug from 2015 to 2019 for persistent disease activity or concomitant rheumatological or dermatological disease. The primary end‐point was effectiveness, based on improvements in inflammatory markers, clinical, and endoscopic remission. The secondary end‐point was safety.Results: Of the 50 patients treated with combination therapy there were significantly more patients in clinical and endoscopic remission at follow‐up compared to baseline (50% vs 14%, P = 0.0018, delta 36%, 95% confidence interval [CI] 0.13‐0.53; and 34% vs 6%, P = 0.0039, delta 28%, 95% CI 0.09‐0.47), respectively. Median erythrocyte sedimentation rate (17 mm/h vs 13 mm/h, P = 0.002) and C‐reactive protein (5.00 mg/dL vs 2.35 mg/dL, P = 0.002) also decreased posttreatment. There were eight serious adverse events and no deathsConclusions: Combination biologic therapy appears to be an effective option for patients with refractory inflammatory bowel disease or concomitant autoimmune disease that is inadequately controlled by biologic monotherapy. There was an increased risk of serious infection compared with biologic monotherapy; however, this risk might be minimized by discontinuing immunomodulators prior to initiating combination therapy. Large prospective studies are needed to confirm these findings.
- 1 April 2020
- Published by Elsevier in JACC: Heart Failure
- Vol. 8 (4) , 313-323
Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients
- 1 April 2020
- Published by Elsevier in JACC: Heart Failure
- Vol. 8 (4) , 313-323
Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients